Individualized Prognostic Insights: CONUT-GBRS for Survival Prediction in Gallbladder Cancer

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-09-12 DOI:10.1002/cam4.71203

Si-qi Yang, Rui-qi Zou, Yu-shi Dai, Jun-ke Wang, Wen-jie Ma, Hai-jie Hu, Fu-yu Li

{"title":"Individualized Prognostic Insights: CONUT-GBRS for Survival Prediction in Gallbladder Cancer","authors":"Si-qi Yang, Rui-qi Zou, Yu-shi Dai, Jun-ke Wang, Wen-jie Ma, Hai-jie Hu, Fu-yu Li","doi":"10.1002/cam4.71203","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The most suitable prognostic prediction system for gallbladder cancer (GBC) is yet to be determined. This study aims to establish a combined score integrating preoperative patients' nutritional and immune status and pathological parameters to forecast the survival outcomes following curative-intent surgery of GBC.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study included patients diagnosed with GBC based on postoperative pathological examinations. The patients underwent curative surgery at West China Hospital of Sichuan University (China) between January 2014 and December 2022. Using the controlling nutritional status (CONUT) score and gallbladder cancer predictive risk score (GBRS), we generated the CONUT-GBRS for every patient, and the patients were divided into two groups based on the optimal cutoff value. Comparisons were made between the two groups regarding clinicopathologic features and survival.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The optimal cutoff value for the CONUT-GBRS was 1.39. There were 99 and 201 individuals in the high and low CONUT-GBRS groups, respectively. Patients with high CONUT-GBRS experienced poorer overall survival and disease-free survival compared with those with low CONUT-GBRS, even after propensity score matching analysis. Both univariate and multivariate Cox analyses established that CONUT-GBRS stood as an independent prognostic factor for GBC patients. Subgroup analysis indicated that CONUT-GBRS was also an effective predictor of prognosis in patients with incidental GBC.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The CONUT-GBRS serves as an advantageous, straightforward, and cost-effective prognostic tool for GBC, offering valuable prognostic insights and guiding the tailoring of individualized treatment strategies to improve patient outcomes.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71203","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71203","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The most suitable prognostic prediction system for gallbladder cancer (GBC) is yet to be determined. This study aims to establish a combined score integrating preoperative patients' nutritional and immune status and pathological parameters to forecast the survival outcomes following curative-intent surgery of GBC.

Methods

This retrospective study included patients diagnosed with GBC based on postoperative pathological examinations. The patients underwent curative surgery at West China Hospital of Sichuan University (China) between January 2014 and December 2022. Using the controlling nutritional status (CONUT) score and gallbladder cancer predictive risk score (GBRS), we generated the CONUT-GBRS for every patient, and the patients were divided into two groups based on the optimal cutoff value. Comparisons were made between the two groups regarding clinicopathologic features and survival.

Results

The optimal cutoff value for the CONUT-GBRS was 1.39. There were 99 and 201 individuals in the high and low CONUT-GBRS groups, respectively. Patients with high CONUT-GBRS experienced poorer overall survival and disease-free survival compared with those with low CONUT-GBRS, even after propensity score matching analysis. Both univariate and multivariate Cox analyses established that CONUT-GBRS stood as an independent prognostic factor for GBC patients. Subgroup analysis indicated that CONUT-GBRS was also an effective predictor of prognosis in patients with incidental GBC.

Conclusion

The CONUT-GBRS serves as an advantageous, straightforward, and cost-effective prognostic tool for GBC, offering valuable prognostic insights and guiding the tailoring of individualized treatment strategies to improve patient outcomes.

Abstract Image

查看原文本刊更多论文

个体化预后洞察：CONUT-GBRS用于胆囊癌的生存预测

背景胆囊癌（GBC）最合适的预后预测系统尚未确定。本研究旨在建立综合术前患者营养、免疫状况及病理参数的综合评分，预测GBC术后的生存结局。方法回顾性研究基于术后病理检查诊断为GBC的患者。患者于2014年1月至2022年12月在四川大学华西医院接受了治疗性手术。利用控制营养状况（CONUT）评分和胆囊癌预测风险评分（GBRS），对每位患者生成CONUT-GBRS，并根据最佳临界值将患者分为两组。比较两组患者的临床病理特征和生存率。结果CONUT-GBRS的最佳临界值为1.39。CONUT-GBRS高组和低组分别有99和201人。与低CONUT-GBRS患者相比，高CONUT-GBRS患者的总生存期和无病生存期较差，即使在倾向评分匹配分析之后也是如此。单因素和多因素Cox分析均证实CONUT-GBRS是GBC患者的独立预后因素。亚组分析表明，CONUT-GBRS也是偶发性GBC患者预后的有效预测因子。结论CONUT-GBRS是一种优势、直接、经济的GBC预后工具，可提供有价值的预后见解，并指导个性化治疗策略的定制，以改善患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.